北京若生智能科技有限公司
Drug Database
MR

MR vaccine (Mebella)

✓ Approved

Indian Immunologicals · 疫苗 · 疫苗

什么是 MR vaccine？

MR vaccine 是一种疫苗，由Indian Immunologicals研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Mebella
公司Indian Immunologicals
药物类别疫苗, 大分子
给药途径Injectable (Others), Subcutaneous Injection
状态Approved
来源： ClinicalTrials.gov, Indian Immunologicals

治疗适应症

MR vaccine 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsMeasles✓ Approved

相关研究文献

PubMedAngewandte Chemie (International ed. in English)2026-09-10

Five-Boron Multiple-Resonance TADF Emitter With Accelerated Reverse Intersystem Crossing for High-Performance Narrowband Green OLEDs.

Lee Taehwan T, Ochi Junki J, Zhang Zishun Z, Kondo Yasuhiro Y et al.

Multiple-resonance thermally activated delayed fluorescence (MR-TADF) emitters are promising candidates for organic light-emitting diodes owing to their narrowband emission and high exciton utilization. While π-conjugated framework expansion has been extensively explored for tuning excited-state properties, five-boron MR-TADF emitters have not yet been realized. Herein, we report the first five-boron MR-TADF emitter, M-DABNA-Mes, featuring an unprecedented odd-numbered boron-rich multiple-resonance framework. Theoretical investigations of one-, three-, and five-boron MR frameworks reveal that incorporation of the fifth boron atom reduces the singlet-triplet energy gap, preserves spin-orbit coupling, and reduces the total reorganization energy while maintaining favorable narrowband emission characteristics. Consistent with these predictions, M-DABNA-Mes doped in a polystyrene film exhibits a sub-microsecond delayed fluorescence lifetime (τTADF = 0.93 µs), a reverse intersystem crossing rate of 2.6 × 106 s-1, and narrow green emission at 512 nm with a full width at half maximum of 19 nm. OLEDs based on M-DABNA-Mes achieve a maximum external quantum efficiency of 34.3% with remarkably low efficiency roll-off (32.3% at 10,000 cd m-2) and a maximum luminance of 275,800 cd m-2. These results demonstrate that the five-boron MR framework enables rapid spin conversion, high spectral purity, and excellent OLED performance, providing a new platform for high-performance MR-TADF emitters.

PMID 42717847
阅读全文 →
PubMedCardiovascular diagnosis and therapy2026-09-10

Association of left ventricular global longitudinal strain with outcomes of severe mitral regurgitation due to severe mitral annular calcification: a retrospective cohort study.

Al Zein Mohammad M, Okushi Yuichiro Y, Unai Shinya S, Pettersson Gösta B GB et al.

Mitral annular calcification (MAC) is associated with increased mortality and a heightened risk of complications such as stroke, myocardial infarction, and arrhythmias. In advanced stages, MAC can cause severe mitral regurgitation (MR), further worsening outcomes. Prognostic markers to guide therapy in this population remain unclear. Left ventricular global longitudinal strain (LVGLS) has been linked to outcomes in MR, but its role in severe MR due to severe MAC is not well established. This study evaluated the prognostic value of LVGLS in this setting. We conducted a single-center, retrospective study of patients with severe MAC identified from the Cleveland Clinic echocardiographic database between January 2010 and August 2023. From these, patients with mild or moderate MR and those with concomitant significant mitral stenosis (MS) were excluded. Subsequently, patients with isolated severe MR due to severe MAC were identified. Clinical and echocardiographic parameters, including LVGLS, were recorded at baseline. The primary outcome was all-cause mortality. Patients were stratified by the median LVGLS value for analysis. Survival was assessed using Kaplan-Meier analysis and Cox proportional hazards models. Restricted cubic spline was used to evaluate potential non-linear associations between LVGLS and mortality. During the study period, 10,061 patients were diagnosed with severe MAC on echocardiography at our institution. Of these, 8,912 with mild or moderate MR and 1,021 with concomitant significant MS were excluded, and 128 patients with isolated severe MR due to severe MAC were included in our study. The median follow-up was 134 days [interquartile range (IQR), 33-1,812 days]. The median age was 81 years (IQR, 71-88 years), and 35 (27.3%) were male. The median left ventricular ejection fraction (LVEF) was 63% (IQR, 56-69%), mean MR regurgitant volume was 60±20.8 mL, and median right ventricular systolic pressure was 54 mmHg (IQR, 42-71 mmHg). The median LVGLS was -14.8%±4.5%. Of the 128 patients, 45 (35.2%) underwent mitral valve intervention, 42 (93.3%) surgery and 3 (6.7%) mitral clip implantation, while 83 (64.8%) received conservative management. Among surgical cases, 37 underwent valve replacements (34 bioprosthetic) and 5 valve repairs. During follow-up, 63 patients (49.2%) died. LVGLS worse than -14.8% was associated with higher 12-month mortality (log-rank P=0.043) but not over the entire follow-up period (P=0.11). On multivariable cox regression, LVGLS was not a predictor of mortality after adjusting for other covariates [hazard ratio (HR) 1.046, 95% confidence interval (CI): 0.983-1.112]. In severe MR due to MAC, impaired LVGLS was associated with increased short-term but not long-term mortality. The limited long-term prognostic value may reflect the low myocardial reserve in patients with severe valvular dysfunction due to MAC, the progressive and systemic nature of the disease, and the influence of non-cardiac comorbidities.

PMID 42718883
阅读全文 →
PubMedFrontiers in immunology2026-09-10

A bivalent oral yeast vaccine displaying Nocardia seriolae FHA and LMBV MCP confers protection in largemouth bass (Micropterus salmoides).

Lu Jianfei J, Gu Boge B, Yu Pengzhen P, Chen Jiong J

Largemouth bass ranavirus (LMBV) and Nocardia seriolae are major pathogens affecting largemouth bass (Micropterus salmoides), causing significant economic losses. In this study, recombinant yeasts expressing the fibronectin-binding protein A (FHA) of N. seriolae or the major capsid protein (MCP) of LMBV were constructed using the yeast surface display (YSD) system. Based on these recombinant strains, a bivalent oral yeast-based vaccine was developed and its protective efficacy was systematically evaluated. Oral administration of the vaccine induced specific antibodies against FHA and MCP in serum, as well as increased the transcription levels of adaptive immune genes (IgM, IgT, MHC-II) and innate immune genes (IL-1β, TNF-α, IFN-1, Mx2) in the hindgut, liver, and spleen. Importantly, the bivalent oral vaccine provided significant protection against both pathogens in largemouth bass, with relative percent survival (RPS) values of 56.7% against N. seriolae and 63.3% against LMBV. Meanwhile, the oral vaccine reduced pathogen loads and alleviated histopathological lesions. In summary, these findings suggest that the bivalent oral vaccine developed in this study could serve as a promising strategy for controlling N. seriolae and LMBV infections in largemouth bass aquaculture.

PMID 42718698
阅读全文 →
PubMedMicrobiology resource announcements2026-09-10

Genomic characterization of the attenuated human cytomegalovirus strain TR-VAC developed for subviral particle vaccine production.

Schmidt Hanno H, Hewel Charlotte C, Büscher Nicole N, Linke Matthias M et al.

We report the complete genome sequence of the attenuated human cytomegalovirus strain TR-VAC, developed for subviral particle vaccine production. Oxford Nanopore duplex sequencing confirmed all engineered modifications, including UL130 repair, UL25 stop codons, ddFKBP insertion, GFP deletion, and retention of the bacterial artificial chromosome backbone, without large-scale structural rearrangements.

PMID 42720293
阅读全文 →
PubMedAsia-Pacific journal of clinical oncology2026-09-10

Augmented Reality, Mixed Reality, Virtual Reality, and Extended Reality Applications in Personalized Oncology and Patient-Centered Cancer Care: A Narrative Review.

Velraj Malarkodi M, Mani Deepalakshmi D, Parthasarathy Arun Kanniyappan AK, Murugesan Vijayakumar V et al.

Extended reality (XR) technologies, including augmented reality (AR), mixed reality (MR), and virtual reality (VR), are an appealing technology in clinical oncology. This narrative review evaluates the current evidence of XR applications throughout the cancer care continuum in terms of the clinical implementation, patient outcome, and the relevance of the practice to practicing clinical oncologists. A literature search on PubMed, Scopus, Web of Science, and Cochrane Library (January 2015-December 2025) was conducted at the right time to select the articles related to AR, VR, MR, XR, and cancer/oncology. Randomized controlled trials (RCTs), systematic reviews, meta-analyses, and clinical implementation studies were given priority. VR contains the strongest evidence base in which 15 RCTs meta-analysis (n = 864) found large reductions in the level of anxiety related to chemotherapy (standardized mean difference [SMD] = -1.40) among adult patients with cancer and fatigue (SMD = -3.85). Cancer-related pain (SMD = -0.86, 95% CI: -1.89 to -0.85, p < 0.001) affected significantly VR interventions as well when implemented in 28 RCTs. In hepatic, glioma, and gastrointestinal tumor resection, AR-guided surgical navigation has been clinically workable, and prospective research has indicated that it is capable of better tumor localization. Depression (SMD = -1.86, p < 0.001) was also reduced. The 3D holographic visualization with the help of MR enables the treatment planning of the multidisciplinary type. The XR technologies possess immense potential in the field of personalized oncology. The sphere of VR-based supportive care intervention is clinically prepared, and still the uses of AR and MR in surgical oncology require confirmation of multicenter trials. Standardization of the protocols, cost-effectiveness studies and its integration into the clinical processes are yet to remain on the list of the top priorities.

PMID 42717530
阅读全文 →
PubMedFrontiers in nutrition2026-09-10

FODMAP intake, gut microbiota, and gastroesophageal reflux disease: a triangulated study of Mendelian randomization and clinical validation.

Chen Yuanchun Y, Lu Shiyun S

Dietary factors related to fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and gut microbiota may influence gastroesophageal reflux disease (GERD), but causal evidence and clinical consistency remain uncertain. We tested whether FODMAP-related and GERD-relevant dietary traits influence GERD risk using Mendelian randomization (MR), and whether gut microbiota mediate these associations. We integrated UK Biobank dietary GWAS, MiBioGen microbiota GWAS, and FinnGen GERD summary statistics using inverse-variance weighted MR, multivariable MR, Benjamini-Hochberg false discovery rate (BH-FDR) correction, MR-Steiger filtering, and two-step mediation analysis. A 525 matched-pair retrospective case-control cohort provided clinical validation. After BH-FDR correction, genetically predicted cheese, cereal, oily fish, fresh/dried fruit, and salad/raw vegetables were associated with lower GERD risk (ORs, 0.46-0.77), whereas tea and poultry were associated with higher risk (ORs, 1.28-2.14). Microbiota-wide and mediation signals did not survive FDR correction. The oily fish-Erysipelatoclostridium indirect effect was small and statistically imprecise (indirect effect, -0.015; 95% CI, -0.034 to 0.005), corresponding to a mediated proportion of 4.1% (95% CI, -1.2 to 9.5%); therefore, it was interpreted as an exploratory signal rather than evidence of a confirmed microbial pathway. Clinical data directionally supported the main dietary signals: tea, poultry, processed meat, and sweets were associated with higher GERD risk (ORs, 1.04-1.19), while cheese, cereal, fruit, and oily fish were protective (ORs, 0.80-0.94). Dietary associations with GERD were more robust than microbiota-associated signals. These findings suggest that oily fish-related dietary patterns may be associated with lower GERD risk, while exploratory analyses provide preliminary evidence that gut microbiota may contribute to these associations. Further studies are required to validate these potential biological pathways.

PMID 42718703
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多MR vaccine